BDBM50526803 CHEMBL4434871::US10870651, Compound 101

SMILES CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3cccc(NC(=O)c4ccc(NC(=O)C=C)cc4)c3)n[nH]c2C1(C)C)c1ccccc1

InChI Key InChIKey=VBYGXNURPHQSPG-MUUNZHRXSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 50526803   

TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Tianjin University of Science and Technology

Curated by ChEMBL
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  20nMAssay Description:Inhibition of CDK7 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Tianjin University of Science and Technology

Curated by ChEMBL
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  7.60nMAssay Description:Inhibition of CDK7 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Lebanese American University

Curated by ChEMBL
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  1.14E+3nMAssay Description:Inhibition of CDK2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Lebanese American University

Curated by ChEMBL
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-K/Cyclin-dependent kinase 9(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHomeodomain-interacting protein kinase 4(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProtein kinase C theta type(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMaternal embryonic leucine zipper kinase(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for activity against a variety of different kinases.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50526803(CHEMBL4434871 | US10870651, Compound 101)
Affinity DataIC50:  7.60nMAssay Description:Inhibition of CDK7/cyclin H/MNAT1 (unknown origin) pre incubated up to 60 mins followed by substrate and ATP additionMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed